Home・Lista de Ações・AbbVie Inc

AbbVie Inc

Abrir

SetorSaúde

243.69 -0.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

242.53

Máximo

247.63

Indicadores-chave
By Trading Economics
Rendimento	-1.1B 697M
Vendas	-1.6B 15B
P/E Médio do Setor	126.557 64.641
EPS	2.65
Rendimento de Dividendos	2.6
Margem de lucro	4.646
Funcionários	57,000
EBITDA	-1.7B 3.7B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+12.63% upside

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	2.60% 2.31%
Próximos Ganhos	30 de out. de 2026
Próxima data de dividendos	14 de ago. de 2026
Próxima data de ex-dividendo	14 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	105B 454B
Abertura anterior	244.13
Fecho anterior	243.69

Sentimento de Notícias

By Acuity

18%

82%

36 / 340 Ranking em Healthcare

AbbVie Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 de jul. de 2026, 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 de jul. de 2026, 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 de jul. de 2026, 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 de jul. de 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 de jul. de 2026, 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24 de jul. de 2026, 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23 de jul. de 2026, 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22 de jul. de 2026, 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21 de jul. de 2026, 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20 de jul. de 2026, 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Comparação entre Pares

Variação de preço

AbbVie Inc Previsão

Preço-alvo

By TipRanks

12.63% parte superior

Previsão para 12 meses

Média 276.05 USD 12.63%

Máximo 300 USD

Mínimo 225 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para AbbVie Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

Comprar

Manter

Vender

Com base em 22 analistas que deram avaliações de ações para AbbVie Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

36 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.